Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, in SCID mouse model for disseminated Mycobacterium avium complex infection.
Emori, M
Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, in SCID mouse model for disseminated Mycobacterium avium complex infection. [electronic resource] - International journal of antimicrobial agents Apr 1998 - 59-65 p. digital
Publication Type: Comparative Study; Journal Article
0924-8579
10.1016/s0924-8579(98)00010-7 doi
Animals
Antibiotics, Antitubercular--therapeutic use
Bacteremia--drug therapy
Disease Models, Animal
Disease Progression
Lung--pathology
Mice
Mice, Inbred BALB C
Mice, Nude
Mice, SCID
Mycobacterium avium Complex--growth & development
Mycobacterium avium-intracellulare Infection--microbiology
Rifamycins--therapeutic use
Species Specificity
Time Factors
Tuberculosis, Pulmonary--drug therapy
Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, in SCID mouse model for disseminated Mycobacterium avium complex infection. [electronic resource] - International journal of antimicrobial agents Apr 1998 - 59-65 p. digital
Publication Type: Comparative Study; Journal Article
0924-8579
10.1016/s0924-8579(98)00010-7 doi
Animals
Antibiotics, Antitubercular--therapeutic use
Bacteremia--drug therapy
Disease Models, Animal
Disease Progression
Lung--pathology
Mice
Mice, Inbred BALB C
Mice, Nude
Mice, SCID
Mycobacterium avium Complex--growth & development
Mycobacterium avium-intracellulare Infection--microbiology
Rifamycins--therapeutic use
Species Specificity
Time Factors
Tuberculosis, Pulmonary--drug therapy